Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Day

Showing results (11-20 of 501) with videos related to

Pageof 51
Sort By:
Clinical and Experimental Rheumatology|November 7, 2001
Pharmacokinetic and pharmacodynamic aspects of the ideal COX-2 inhibitor: a rheumatologist's perspectiveR O Day
The Journal of Rheumatology|May 3, 2015
Prednisone for cardiac failure in patients with hypertensionRichard O Day
Therapeutic Innovation & Regulatory Science|September 21, 2018
Introduction to the Special Section: Phase I Clinical TrialsRichard O Day
Journal of Clinical Pharmacology|May 1, 1979
Deafness due to aspirinR O Day
Australian Prescriber|December 28, 2023
Ongoing challenges of off-label prescribingRichard O Day
BMJ (Clinical Research Ed.)|November 25, 2017
A man with paraesthesia, headache, and vertigoJacob O Day, Pragnesh Bhatt
Australian Prescriber|June 28, 2016
Where to find information about drugsRichard O Day, Leone Snowden
Annals of the Rheumatic Diseases|April 4, 2014
Response to A. G. Helg's comments on the LEGS studyMarlene Fransen, Richard O Day
The Medical Journal of Australia|November 23, 2000
COX-2 inhibitorsP M Brooks, R O Day
Drugs & Aging|March 1, 1991
The problems and pitfalls of NSAID therapy in the elderly (Part I)A G Johnson, R O Day
Pageof 51

Showing results (11-20 of 501) with videos related to

Sort By:
Pageof 51
Clinical and Experimental Rheumatology|November 7, 2001
Pharmacokinetic and pharmacodynamic aspects of the ideal COX-2 inhibitor: a rheumatologist's perspectiveR O Day
The Journal of Rheumatology|May 3, 2015
Prednisone for cardiac failure in patients with hypertensionRichard O Day
Therapeutic Innovation & Regulatory Science|September 21, 2018
Introduction to the Special Section: Phase I Clinical TrialsRichard O Day
Journal of Clinical Pharmacology|May 1, 1979
Deafness due to aspirinR O Day
Australian Prescriber|December 28, 2023
Ongoing challenges of off-label prescribingRichard O Day
BMJ (Clinical Research Ed.)|November 25, 2017
A man with paraesthesia, headache, and vertigoJacob O Day, Pragnesh Bhatt
Australian Prescriber|June 28, 2016
Where to find information about drugsRichard O Day, Leone Snowden
Annals of the Rheumatic Diseases|April 4, 2014
Response to A. G. Helg's comments on the LEGS studyMarlene Fransen, Richard O Day
The Medical Journal of Australia|November 23, 2000
COX-2 inhibitorsP M Brooks, R O Day
Drugs & Aging|March 1, 1991
The problems and pitfalls of NSAID therapy in the elderly (Part I)A G Johnson, R O Day
Pageof 51